BioCentury
ARTICLE | Clinical News

Gattex teduglutide regulatory update

February 4, 2013 8:00 AM UTC

A panel of experts convened in a roundtable sponsored by NPS published guidelines in the Journal of Parenteral and Enteral Nutrition on integrating Gattex teduglutide into the management of short bowel syndrome (SBS). The authors concluded that integrating Gattex into a coordinated approach to treat SBS may result in more success rehabilitating the intestine and weaning from parenteral nutrition/IV fluids. The guidelines list criteria for determining appropriate patients for treatment with Gattex, including that the patient is clinically stable, has persistent need for parenteral nutrition/IV despite optimized therapy, be nutritionally optimized and in fluid balance, and desires to reduce or discontinue parenteral nutrition/IV. The guidelines recommend that physicians establish baseline parameters on nutrients and liver function prior to initiating Gattex therapy and monitor the parameters closely throughout the weaning process. The authors also recommend that physicians refer patients to major centers with experience in intestinal rehabilitation. ...